US investigators have suggested that lowering serum C-reactive protein (CRP) levels (with statins or other anti-inflammatory agents) could reduce vascular risk in patients with acute coronary syndromes. The PROVE IT-TIMI 22 Investigators studied serum CRP and LDL cholesterol levels in 3745 patients receiving statin therapy (80 mg atorvastatin or 40 mg pravastatin, daily) after an acute myocardial infarction or for unstable angina. Irrespective of the serum LDL cholesterol level achieved, patients with low (< 2mg/L) serum CRP levels after statin therapy had better clinical outcomes than those with higher levels.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
